Download PDF
Thromb Haemost 2015; 113(05): 1149-1151
DOI: 10.1160/TH14-10-0869
Letters to the Editor
Schattauer GmbH

Chromogenic assays for measurement of rivaroxaban from EDTA anticoagulated plasma samples

Shanshan Du
1   Clinical Pharmacology Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany
,
Sandra Krämer
1   Clinical Pharmacology Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany
,
Christina Giese
1   Clinical Pharmacology Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany
,
Christel Weiss
2   Biometry and Statistics, Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany
,
Martin Wehling
1   Clinical Pharmacology Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany
,
Roland Krämer
3   Institute Inorganic Chemistry, University of Heidelberg, Heidelberg, Germany
,
Job Harenberg
1   Clinical Pharmacology Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany
› Author Affiliations
Further Information

Publication History

Received: 21 October 2014

Accepted after minor revision: 10 January 2014

Publication Date:
24 November 2017 (online)

    Permissions and Reprints
 

  • References

  • 1 Samama MM, Contant G, Spiro TE. et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Barrett YC, Wang Z, Frost C. et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263-1271.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Douxfils J, Tamigniau A, Chatelain B. et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723-731.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Rosen S. Chromogenic methods in coagulation diagnostics. Haemostaseologie 2005; 25: 259-266.
    PubMedGoogle Scholar
  • 5 Harenberg J, Marx S, Weiss C. et al. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 2012; 10: 1433-1436.
    CrossrefPubMedGoogle Scholar
  • 6 Harenberg J, Kramer S, Du S. et al. Measurement of rivaroxaban and apixaban in serum samples of patients. Eur J Clin Invest 2014; 44: 743-752.
    CrossrefPubMedGoogle Scholar